Prognostic factors in non-metastatic HER2 'low' and HER2 'negative' breast cancer: single institute experience.
Wien Klin Wochenschr
; 136(11-12): 340-346, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38180508
ABSTRACT
AIM:
Comparison of prognosis and survival in human epidermal growth factor receptor 2 (HER2)-low and HER2-negative patients with early stage or locally advanced, hormone receptor-positive breast cancer. MATERIAL ANDMETHODS:
In a retrospective single center study, the patients with early stage or locally advanced stage, hormone receptor (HR)-positive [estrogen receptor (ER) ≥â¯1% and/or progesterone receptor (PR) ≥â¯1%] and HER2 negative or HER2 low invasive breast cancer diagnosis were included. A total of 444 patients were included in the study. Patients were divided into two groups HER2 negative and HER2 low. There were 235 (53%) patients in the HER2 negative group and 209 (47%) patients in the HER2 low group.RESULTS:
The HER2 low group had significantly longer 5year disease-free survival (DFS) than the HER2 negative group. The patients with lower Ki67 (<â¯20%) also had a longer 5year DFS.CONCLUSION:
Nonmetastatic HR+/HER2 low breast cancer patients had better DFS than HR+/HER2 negative ones. The Ki67 level and HER2 low status were independent prognostic factors. Randomized clinical trials are needed in early stage HER2 low breast cancer patients.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Biomarcadores de Tumor
/
Receptor ErbB-2
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Wien Klin Wochenschr
Año:
2024
Tipo del documento:
Article
País de afiliación:
Turquía